Cook Group said today that it completed the sale of Cook Pharmica to Catalent (NYSE:CTLT). Catalent announced last month that it planned to dish out $950 million to buy the biologics contract manufacturer. The newly-acquired company will be called Catalent Bloomington, according to Cook Group. Get the full story at our sister site, Drug Delivery Business News.
Catalent today priced an underwritten public offering for 6,395,000 shares of its common stock at $39.10 apiece. The offering will be used to fund, in part, the drug-delivery company’s $950 million purchase of biologics manufacturer, Cook Pharmica. In connection with the offering, Catalent granted underwriters a 30-day option to buy up to an additional 959,250 shares of […]
Catalent said today that it launched an underwritten public offering for $250 million of its common stock to fund, in part, its $950 million purchase of biologics manufacturer Cook Pharmica. In connection with the offering, Catalent is slated to grant underwriters a 3o-day option to buy up to $37.5 million of additional shares of common stock. Get […]